|Day Low/High||98.83 / 103.00|
|52 Wk Low/High||86.02 / 136.26|
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
Not every trade can be a winner, so let's lighten the load here.
Analysts weren't shy to defend the company after Tuesday's earnings.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.